2,4-dichloro-5-nitroquinazoline | 1596737-83-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 2,4-dichloro-5-nitroquinazoline
• 英文别名: 2,4-Dichloro-5-nitroquinazoline
• CAS: 1596737-83-5
• 化学式: C₈H₃Cl₂N₃O₂
• 分子量: 244.037
• InChiKey: GFQCKTKCUQZSOG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  71.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2,4-dichloro-5-nitroquinazoline 在 ammonium chloride 、 sodium methylate 作用下， 生成 2-chloro-4-methoxy-quinazolin-5-amine
  参考文献：
  名称：

  QUINAZOLINONES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME

  摘要：

  Disclosed are compounds and pharmaceutically acceptable salts thereof that may be used in the treatment of subjects in need thereof. The compounds disclosed herein may be inhibitors of tyrosine and threonine-specific cdc2-inhibitory kinase (Myt1). Also disclosed are pharmaceutical compositions containing the compounds or pharmaceutically acceptable salts thereof and methods of their preparation and use.

  公开号：

  US20230348456A1
• 作为产物：
  描述：

  2-氨基-6-硝基苯甲酸 在 尿素 、 N,N-二乙基苯胺 作用下， 生成 2,4-dichloro-5-nitroquinazoline
  参考文献：
  名称：

  QUINAZOLINONES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME

  摘要：

  Disclosed are compounds and pharmaceutically acceptable salts thereof that may be used in the treatment of subjects in need thereof. The compounds disclosed herein may be inhibitors of tyrosine and threonine-specific cdc2-inhibitory kinase (Myt1). Also disclosed are pharmaceutical compositions containing the compounds or pharmaceutically acceptable salts thereof and methods of their preparation and use.

  公开号：

  US20230348456A1

文献信息

• QUINAZOLINONES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME
  申请人：Repare Therapeutics Inc.

  公开号：US20230348456A1

  公开（公告）日：2023-11-02

  Disclosed are compounds and pharmaceutically acceptable salts thereof that may be used in the treatment of subjects in need thereof. The compounds disclosed herein may be inhibitors of tyrosine and threonine-specific cdc2-inhibitory kinase (Myt1). Also disclosed are pharmaceutical compositions containing the compounds or pharmaceutically acceptable salts thereof and methods of their preparation and use.